ArticleMolecular biotechnology2026
An Integrated Computational and Biophysical Approach for Investigating the Structure-Function Impact of blaOXA-58 Mutations in Acinetobacter baumannii.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine Learning-Driven Discovery of Novel HER2 Inhibitors Through Integrated Virtual Screening and Molecular Dynamics Simulations.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenems are the last-resort antibiotic option against A. baumannii infections, and Carbapenem resistance leads to the emergence of CRAB strains, which are difficult to treat. The CRAB novel reported mutation in the blaOXA-58, whose resistance mechanism was not explored. Here, we conducted molecular docking and molecular dynamics simulation to unveil and compare the molecular mechanisms of blaOXA-58 wild and mutant types (I87M, A88L, and double-mutated). The crystal structure of blaOXA-58 was retrieved from PDB, mutations were induced using the AlphaFold online server, and the structures of Carbapenem drugs (DOR, ETP, MEM, and IPM) were retrieved from PubChem database. Using PyRx 0.8, molecular docking was performed between Carbapenem drugs and protein blaOXA-58, both in wild-type and mutant variants. The results were validated through molecular dynamics simulations lasting 100 ns. Docking results showed the binding score of Carbapenem drugs with wild-type blaOXA-58 protein, I87M, A88L, and double-mutated forms, which revealed that the single mutation enhanced the binding affinity of Carbapenems toward the protein. Meanwhile, the decreased binding affinity of Carbapenem toward the double-mutated protein may be due to combined effect of the mutations on the protein structure. Overall, Ertapenem showed good binding scores (-8.1, -8.8, -8.8, and -6.1 kcal/mol), and Imipenem showed weak affinity (-6.3, -5.6, -6.3, and -5 kcal/mol) toward wild-type protein, I87M, A88L, and the double-mutated blaOXA-58 protein, respectively. Wild and double-mutated complexes were subjected to molecular dynamics simulation which revealed mutant-ETP was the most stable complex with low RMSD, RMSF, RoG, and B-factor values. PCA showed reduced flexibility, mutation affected surface loop arrangements in mutant complexes, raising SASA in DOR/IPM, reducing it in ETP, minimal effect in MEM. In contrast, mutant-IPM had higher RMSD, RMSF, RoG, lower hydrogen bonding, and better flexibility. Mutant-DOR exhibited a loss of α-helices and β-strands. The outcomes of the current analysis demonstrated that slight mutation in blaOXA-58 affects working of carbapenem antibiotic. The complicated impact of the double mutation on stability and binding should improve antibiotic-resistant pathogen research by enhancing targeted medication or inhibitor design.
Indexed as
Identifiers
41575723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.